This study suggests a potential benefit of etanercept in postmenopausal women. Reduction in bone resorption by anatomically targeted TNF-blockade was suggested by me as a possible mechanism underlying the clinical response I observed in two patients with malignant spinal metastasis whom I treated with perispinal etanercept (Tobinick EL, Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 2003 Aug; 25(8) :2279-88), so the results of this new study are not surprising. The overall use of anakinra has not fulfilled initial expectations, probably due to both its need for frequent administration, the availability of alternative biologic therapeutics, and its known potential toxicity; this report, therefore, with respect to anakinra, is of academic interest, but is unlikely to result in significant changes in clinical prescribing.
Title Effect of Blockade of Tumor Necrosis Factor-alpha and Interleukin-1 Action on Bone Resorption in Early Postmenopausal Women.
Author(s) Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL
Source J Bone Miner Res 2007 Feb 12.
Abstract Microabstract After acute estrogen withdrawal in postmenopausal women, administration of anakinra or etanercept, specific blockers of IL-1 and TNF-alpha, respectively, reduced the rise in bone resorption markers to about half of that in controls. This is consistent with an important role for these immune cytokines in mediating the effect of estrogen deficiency on bone.
Language ENG
Pub Type(s) JOURNAL ARTICLE
PubMed ID 17295604
Comments